Sanofi's Dupixent Gets EU Approval as First Targeted Medicine
Ticker: SNYNF · Form: 6-K · Filed: Dec 3, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, pharmaceuticals, drug-development
Related Tickers: REGN
TL;DR
Sanofi's Dupixent approved in EU as first targeted therapy - big win!
AI Summary
On November 25, 2025, Sanofi announced that its drug Dupixent, developed with Regeneron, received approval in the European Union as the first targeted medicine for a specific condition. This marks a significant milestone for the company and its partner in expanding treatment options.
Why It Matters
This approval signifies a breakthrough in targeted therapy for a specific disease in the EU, potentially improving patient outcomes and expanding Sanofi's market reach.
Risk Assessment
Risk Level: low — This filing is an informational report (6-K) about a regulatory approval and does not contain significant financial or operational changes that would inherently increase risk.
Key Players & Entities
- Sanofi (company) — Registrant and developer of Dupixent
- Regeneron (company) — Partner in the development of Dupixent
- Dupixent (company) — Drug developed by Sanofi and Regeneron
- November 25, 2025 (date) — Date of the press release regarding Dupixent approval
- European Union (location) — Region where Dupixent received approval
FAQ
What specific condition has Dupixent been approved for in the EU?
The filing states Dupixent was approved as the 'first targeted medicine in the EU in over a de', but the specific condition is not detailed in this excerpt.
When was the press release announcing this approval issued?
The press release was dated November 25, 2025.
Which regulatory body granted the approval for Dupixent?
The approval was granted by the European Union.
Is this a 20-F or 40-F filing?
This is a Form 6-K filing, and the company indicates it files annual reports under Form 20-F.
What is Sanofi's principal executive office address?
Sanofi's principal executive offices are located at 46, avenue de la Grande Armée, 75017 Paris, FRANCE.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2025-12-03 11:30:33
Filing Documents
- d45406d6k.htm (6-K) — 8KB
- d45406dex991.htm (EX-99.1) — 38KB
- g45406g1203020912329.jpg (GRAPHIC) — 3KB
- 0001193125-25-306193.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 3, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3